CA1064904A - Sulphated saponine salts, process for obtention and medicine - Google Patents
Sulphated saponine salts, process for obtention and medicineInfo
- Publication number
- CA1064904A CA1064904A CA256,652A CA256652A CA1064904A CA 1064904 A CA1064904 A CA 1064904A CA 256652 A CA256652 A CA 256652A CA 1064904 A CA1064904 A CA 1064904A
- Authority
- CA
- Canada
- Prior art keywords
- escin
- acid ester
- sulphating
- molecule
- ester groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- SYXUBXTYGFJFEH-UHFFFAOYSA-N oat triterpenoid saponin Chemical class CNC1=CC=CC=C1C(=O)OC1C(C=O)(C)CC2C3(C(O3)CC3C4(CCC5C(C)(CO)C(OC6C(C(O)C(OC7C(C(O)C(O)C(CO)O7)O)CO6)OC6C(C(O)C(O)C(CO)O6)O)CCC53C)C)C4(C)CC(O)C2(C)C1 SYXUBXTYGFJFEH-UHFFFAOYSA-N 0.000 title description 4
- 239000003814 drug Substances 0.000 title description 3
- 229940011399 escin Drugs 0.000 claims abstract description 98
- 229930186222 escin Natural products 0.000 claims abstract description 98
- 150000002148 esters Chemical class 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 239000002253 acid Substances 0.000 claims abstract description 23
- 239000001117 sulphuric acid Substances 0.000 claims description 17
- 235000011149 sulphuric acid Nutrition 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 12
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002585 base Substances 0.000 claims description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 230000000875 corresponding effect Effects 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000023555 blood coagulation Effects 0.000 abstract description 2
- 230000005786 degenerative changes Effects 0.000 abstract description 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 230000008736 traumatic injury Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 206010018852 Haematoma Diseases 0.000 description 3
- 229920001499 Heparinoid Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- 230000002322 anti-exudative effect Effects 0.000 description 3
- 230000001741 anti-phlogistic effect Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000002554 heparinoid Substances 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 235000010181 horse chestnut Nutrition 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- -1 ~orexample Substances 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 241000157280 Aesculus hippocastanum Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010057267 Periphlebitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010042345 Subcutaneous haematoma Diseases 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 239000001524 citrus aurantium oil Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000000332 continued effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- KHDOTPVDSFBNMG-UHFFFAOYSA-N ethanol;pyridine Chemical compound CCO.C1=CC=NC=C1 KHDOTPVDSFBNMG-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752530954 DE2530954A1 (de) | 1975-07-11 | 1975-07-11 | Sulfatierte saponinsalze, verfahren zur herstellung und arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1064904A true CA1064904A (en) | 1979-10-23 |
Family
ID=5951226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA256,652A Expired CA1064904A (en) | 1975-07-11 | 1976-07-09 | Sulphated saponine salts, process for obtention and medicine |
Country Status (19)
-
1975
- 1975-07-11 DE DE19752530954 patent/DE2530954A1/de not_active Withdrawn
-
1976
- 1976-06-30 PT PT65300A patent/PT65300B/pt unknown
- 1976-07-05 FI FI761956A patent/FI761956A7/fi not_active Application Discontinuation
- 1976-07-05 BG BG033671A patent/BG27377A3/xx unknown
- 1976-07-06 CS CS764472A patent/CS193552B2/cs unknown
- 1976-07-07 GB GB28231/76A patent/GB1492023A/en not_active Expired
- 1976-07-07 SU SU762378552A patent/SU614741A3/ru active
- 1976-07-08 AU AU15731/76A patent/AU504838B2/en not_active Expired
- 1976-07-08 ZA ZA764063A patent/ZA764063B/xx unknown
- 1976-07-08 YU YU01668/76A patent/YU166876A/xx unknown
- 1976-07-09 HU HU76MA2795A patent/HU174602B/hu unknown
- 1976-07-09 CA CA256,652A patent/CA1064904A/en not_active Expired
- 1976-07-10 RO RO7686930A patent/RO70425A/ro unknown
- 1976-07-10 PL PL1976191112A patent/PL99630B1/pl unknown
- 1976-07-12 BE BE168850A patent/BE844054A/xx unknown
- 1976-07-12 PH PH18680A patent/PH12629A/en unknown
- 1976-07-12 FR FR7621312A patent/FR2316960A1/fr active Granted
- 1976-07-12 JP JP51082844A patent/JPS5236655A/ja active Granted
-
1978
- 1978-08-31 HK HK491/78A patent/HK49178A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SU614741A3 (ru) | 1978-07-05 |
| PT65300B (de) | 1977-12-13 |
| AU504838B2 (en) | 1979-11-01 |
| ZA764063B (en) | 1977-07-27 |
| BG27377A3 (bg) | 1979-10-12 |
| BE844054A (fr) | 1977-01-12 |
| HK49178A (en) | 1978-09-08 |
| DE2530954A1 (de) | 1977-01-27 |
| GB1492023A (en) | 1977-11-16 |
| FR2316960B1 (enrdf_load_stackoverflow) | 1979-03-02 |
| CS193552B2 (en) | 1979-10-31 |
| PH12629A (en) | 1979-07-05 |
| PT65300A (de) | 1976-07-01 |
| HU174602B (hu) | 1980-02-28 |
| FI761956A7 (enrdf_load_stackoverflow) | 1977-01-12 |
| FR2316960A1 (fr) | 1977-02-04 |
| JPS5614117B2 (enrdf_load_stackoverflow) | 1981-04-02 |
| YU166876A (en) | 1982-05-31 |
| JPS5236655A (en) | 1977-03-22 |
| RO70425A (ro) | 1980-12-30 |
| PL99630B1 (pl) | 1978-07-31 |
| AU1573176A (en) | 1978-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69610370T3 (de) | Mit Antioxidantien gepfropfte Polysaccharide und deren Verwendungen | |
| CA1079723A (en) | Polygalactosido-sucrose poly (h-) sulfate salts | |
| KR101235968B1 (ko) | 피르페니돈을 포함하는 겔 | |
| JPH0317825B2 (enrdf_load_stackoverflow) | ||
| DE1768806A1 (de) | Als Antikoagulans und/oder Lipaemiegegenmittel wirksamer Heparinoid-Komplex | |
| GB1570627A (en) | Polysaccharide derivatives of anaesthetic compounds | |
| US5474782A (en) | Wound-healing composition and method | |
| DE2433407A1 (de) | Sulfate von hydroxyaethylstaerke | |
| WO1992002231A1 (fr) | Agent anti-vih | |
| US3275643A (en) | Allantoin-pantothenate compounds | |
| DE3014045A1 (de) | Fuer kosmetische zwecke verwendbare praeparate und verfahren zur herstellung der wirkstoffe dieser praeparate | |
| CN104125964B (zh) | 部分解聚的糖胺聚糖银盐和金盐 | |
| CA1064904A (en) | Sulphated saponine salts, process for obtention and medicine | |
| CN116003830A (zh) | 超吸收性水凝胶及其制备方法和应用 | |
| CH616931A5 (en) | Process for the preparation of 2,4-diamino-5-benzylpyrimidines acting as potentiator for sulphonamides. | |
| KR790001714B1 (ko) | 사포닌 황산 에스테르염류의 제조방법 | |
| EP1762273A2 (en) | Cosmetic peeling compositions | |
| CN109847067B (zh) | 一种双氯芬酸-甘氨酸-白藜芦醇偶联物、制备方法及应用 | |
| DE69313138T2 (de) | Oligosaccharide mit biologischer aktivität und verfahren zur herstellung aus glykosaminoglykanen | |
| DE69824580T2 (de) | Verwendung einer kondensationspolymär zur verhütung | |
| EP0029990B1 (de) | Diphenylmethanderivat, Verfahren zu seiner Herstellung und es enthaltende Arzneimittel | |
| CN118903000B (zh) | 水杨酸离子液体纯水溶液制剂、其制备方法及其应用 | |
| DE828549C (de) | Verfahren zur Herstellung von racemischem threo-1-(5'-Nitro-2'-thienyl)-2-dichloracetylamino-propandiol-(1,3) | |
| US3812099A (en) | Polymer derivative of 1-methyl-5/5-oxo-4-ethyl-tetrahydrofuryl-(3)-methyl/imidazole with cellulose glycolic acid | |
| JP2511675B2 (ja) | ポリオキシエチレン化キチンの製造方法 |